Prosecution Insights
Last updated: July 17, 2026
Application No. 18/640,764

COSMETIC ESTER COMPOSITION

Non-Final OA §103
Filed
Apr 19, 2024
Priority
Apr 21, 2023 — TW 112115039
Examiner
ROSENTHAL, ANDREW S
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Patech Fine Chemicals Co. Ltd.
OA Round
1 (Non-Final)
51%
Grant Probability
Moderate
1-2
OA Rounds
9m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
339 granted / 659 resolved
-8.6% vs TC avg
Strong +41% interview lift
Without
With
+40.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
43 currently pending
Career history
699
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
68.9%
+28.9% vs TC avg
§102
0.9%
-39.1% vs TC avg
§112
1.1%
-38.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 659 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgement is made of the Applicant’s claim of foreign priority to application TW112115039 filed 21 April 2023. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-9 are rejected under 35 U.S.C. 103 as being unpatentable over Malle et al. (US 8,790,625). Malle teaches a composition comprising a polycondensate of Example 1 (29g; equivalent to 29% by weight) and tridecyl trimellitate (qs to 100g; equivalent to 18 g or 18% by weight) for use as a cosmetic composition (col 21, lns 29-40). The polycondensate is prepared by reacting pentaerythritol with isostearic acid, benzoic acid, and isophthalic acid in an esterification reaction to form an oil that comprises pentaerythritol esters with carbon chains with a mixture of C6 and C17 lengths and some of the pentaerythritol linked via isophthalic acid chains (col 17, lns 11-31). More broadly, the polycondensate can be made from any polyol including glycerol, pentaerythritol, and dipentaerythritol as well as a mixture of carboxylic acids that can range in length including octanoic acid (C8) and isostearic acid (C17) (col 9, lns 7-56). The overall polycondensate is required to have a hydroxyl number (interpreted as the same as hydroxyl value) of preferably between 40-120 mg KOH/g and a viscosity between 50-2500 mPa-s (col 10, lns 19-43). It would have been prima facie obvious to prepare the cosmetic composition of Example 8 and adapt it to meet the hydroxyl value and viscosity requirements of Malle. The broad ranges provided by Malle overlap with the claimed values. In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976). MPEP 2144.05 (I). Regarding the selection of polycondensate components, the prior art teaches a broad variety of polyols and carboxylic acids however it would have been obvious to select a combination of glycerol, pentaerythritol, and dipentaerythritol as well as a mixture of carboxylic acids that can range in length including octanoic acid (C8) and isostearic acid (C17). That being said, it must be remembered that “[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious.” KSR v. Teleflex, 127 S.Ct. 1727, 1740 (2007) (quoting Sakraida v. A.G. Pro, 425 U.S. 273, 282 (1976)). “[W]hen the question is whether a patent claiming the combination of elements of prior art is obvious,” the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR at 1741. The Court emphasized that “[a] person of ordinary skill is… a person of ordinary creativity, not an automaton.” Id. at 1742. Consistent with this reasoning, it would have been obvious to have selected various combinations of polyols and carboxylic acids from within Malle, to arrive at compositions “yielding no more than one would expect from such an arrangement.” The resulting composition, wherein the polyol can be any of glycerol, pentaerythritol, and dipentaerythritol, renders obvious instant claims 1-9. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW S ROSENTHAL whose telephone number is (571)272-6276. The examiner can normally be reached M-F 8-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian Kwon can be reached at 571-272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREW S ROSENTHAL/ Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Apr 19, 2024
Application Filed
Jun 22, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12667627
NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS
2y 8m to grant Granted Jun 30, 2026
Patent 12653837
Use Of Inhaled Nitric Oxide And Oxygen For The Treatment Of Pulmonary Hypertension
5y 11m to grant Granted Jun 16, 2026
Patent 12653784
DETERMINATION OF THE TRAPPED VOLUME OF A LIPOSOME
1y 11m to grant Granted Jun 16, 2026
Patent 12648920
METHODS OF ADMINISTERING GLUTATHIONE PRECURSORS
3y 3m to grant Granted Jun 09, 2026
Patent 12648899
COSMETIC SALTS
2y 11m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
51%
Grant Probability
92%
With Interview (+40.6%)
3y 0m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 659 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month